Bis vor drei Jahren behauptete sich Peugeot sieben Jahre lang als Spitzenreiter im europäischen Kleinwagen-Segment. Von der 200er-Baureihe wurden in den letzten 30 Jahren über 15 Millionen Fahrzeuge abgesetzt und war damit der vermeintliche Garant für ein profitables Geschäft des französischen Herstellers. Doch nicht nur der Wettbewerb verschärfte sich, auch der 207 erfüllte die fast als selbstverständlich erwarteten Verkaufszahlen nicht. Der im Frühjahr eingeführte neue 208 soll es nun wieder richten und die ersten Verkaufszahlen machen Hoffnung. Zur Flankenabsicherung schieben die Franzosen nun ab Mitte Juni den 2008 nach. Peugeot nennt ihn Urban-Crossover, was übersetzt eine Mixtur aus Mini-SUV, Mini-Van und konventionellem Kleinwagen bedeutet. Ein Segment, das in Deutschland innerhalb der vergangenen fünf Jahre nahezu kontinuierlich gewachsen ist und weiterhin hohes Wachstumspotenzial verspricht. Es hat sich eben mittlerweile herumgesprochen, dass diese Fahrzeuge in der Regel eben mehr Platz als erwartet bieten und dank der Kompaktheit nichts an Agilität und Wendigkeit eingebüßt haben.
When IIHS began its booster seat ratings in 2008, most models failed to consistently provide good belt fit — the main purpose of a booster. This year, all new models evaluated by the Institute provide good or acceptable fit for typical 4 to 8 year-olds in most cars, minivans or SUVs.
Out of 23 new models evaluated, 20 earn the highest rating of BEST BET, meaning they are likely to provide good fit for a 4- to 8-year-old child in almost any car, minivan or SUV. Another three models are rated GOOD BETs, meaning they provide acceptable fit in most vehicles. There are no new models in the Not Recommended category, nor are there any with the Check Fit designation, which identifies seats that may work for some children in some vehicles.
Northwestern Medicine’s Bluhm Cardiovascular Institute is celebrating the success of its transcatheter valve program, a pioneering technology that replaces or repairs leaky heart valves without open-heart surgery. On August 25, 2016, more than 50 former transcatheter valve replacement patients and their family members celebrated the life-saving procedure that has extended both their lives and their ability to enjoy them.
The Bluhm Cardiovascular Institute hit the milestone of being the first hospital in Illinois to perform the 500th TAVR, or transcatheter aortic valve replacement, since the program’s inception in 2008. Charles J. Davidson, MD, performed the 500th procedure on July 23, 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7049452-northwestern-medicine-transcatheter-valve/
The following statement is being issued by Branstetter, Stranch & Jennings, PLLC regarding In re Prograf Antitrust Litigation.
A lawsuit is currently pending claiming that Astellas Pharma US, Inc. (“Astellas” or “Defendant”) violated state antitrust, unfair competition, consumer protection, and unjust enrichment laws of certain states by delaying the availability of a less expensive generic version of the immunosuppressant prescription drug Prograf® (known as tacrolimus). Plaintiffs allege that Defendant’s conduct caused some consumers and third party payors to pay too much for Prograf in certain states from September 3, 2008 to December 31, 2010 (also referred to as the “Class Damage Period”). This lawsuit does not claim that Prograf is unsafe or ineffective. Astellas denies any wrongdoing.
To view the multimedia release go to:
http://www.multivu.com/players/English/7933851-prograf-antitrust-class-action-settlement/
